Clarivate sells its Life Sciences & Healthcare unit for $600M to refocus on IP data

On October 6, 2026, Clarivate completed the sale of its Life Sciences & Healthcare segment to Altaris, LLC for $600 million — $500 million in cash at closing, a $75 million unsecured senior note and $25 million in deferred consideration, subject to customary adjustments. The divestiture coincided with the departure of Henry Levy, the segment's president, and leaves the company focused on its two remaining businesses: Academia & Government and Intellectual Property, home to products such as Web of Science, ProQuest, Derwent and CompuMark.

The context is a company in repair. TipRanks' analysis flags shrinking revenue and ongoing net losses as the fundamental overhang for a stock near a $946.7 million market cap, even as cash generation improves. Management said the proceeds will reduce debt and strengthen the balance sheet, supporting a subscription-first model built on proprietary content, workflow software and expanding AI capabilities — aimed at improving revenue quality, expanding profitability and repositioning Clarivate as a more focused, higher-margin information and analytics provider.

The company framed the completed sale as a key milestone in its value-creation plan. The structural logic runs both ways: Clarivate sheds a segment outside its core research-and-IP franchise, and the Life Sciences & Healthcare operations land with a specialised financial sponsor rather than being wound down.

$600 million from Altaris — $500M cash at closing, a $75M unsecured senior note and $25M deferred — earmarked for debt reduction and a subscription-first model.

The sale was executed, not announced — cash received at closing makes the portfolio decision real and immediately funds debt reduction.

Two segments remain where three stood, ending the distraction of a healthcare business that did not share the subscription economics of the core.

The segment president's departure with the sale signals a clean break rather than a shared-services arrangement.

Taking $100M of the price as a note and $25M deferred shows the buyers' structure, with Clarivate prioritising balance-sheet repair over a full cash exit.

When a three-segment information company carries a segment that shrinks faster than the rest, selling it complete to a specialist owner converts the drag into deleveraging capital.

As of the October 6, 2026 completion, proceeds were earmarked for debt reduction; no post-sale revenue or margin figures for the remaining segments are reported in the material.